Optimized production of T cells expressing chimeric antigen receptors through PI3K inhibition with idelalisib

被引：0

作者：

Stock, S. ^{[1
]}

Hoffmann, J. -M. ^{[1
]}

Gern, U. ^{[1
]}

Wang, L. ^{[1
]}

Hueckelhoven, A. ^{[1
]}

Neuber, B. ^{[1
]}

Schubert, M. -L. ^{[1
]}

Schmitt, A. ^{[1
]}

Mueller-Tidow, C. ^{[1
]}

Dreger, P. ^{[1
]}

Schmitt, M. ^{[1
]}

Sellner, L. ^{[1
]}

机构：

[1] Heidelberg Univ Hosp, Dept Internal Med 5, Heidelberg, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V723

引用

页码：212 / 212

页数：1

共 50 条

[21] Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients
Stock, Sophia
Uebelhart, Rudolf
Schubert, Maria-Luisa
Fan, Fuli
He, Bailin
Hoffmann, Jean-Marc
Wang, Lei
Wang, Sanmei
Gong, Wenjie
Neuber, Brigitte
Hueckelhoven-Krauss, Angela
Gern, Ulrike
Christ, Christiane
Hexel, Monika
Schmitt, Anita
Schmidt, Patrick
Krauss, Juergen
Jaeger, Dirk
Mueller-Tidow, Carsten
Dreger, Peter
Schmitt, Michael
Sellner, Leopold
INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (05) : 1312 - 1324
[22] PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt
Uche, Uzodinma U.
Piccirillo, Ann R.
Kataoka, Shunsuke
Grebinoski, Stephanie J.
D'Cruz, Louise M.
Kane, Lawrence P.
JOURNAL OF EXPERIMENTAL MEDICINE, 2018, 215 (12): : 3165 - 3179
[23] Inhibition of the transcription factor Ikaros augments the tumoricidal capacity of CD8+T cells expressing chimeric antigen receptors
O'Brien, Shaun
Wang, Liang-Chuan
Newick, Kheng
Thomas, Rajan M.
Wells, Andrew
Albelda, Steven M.
CANCER RESEARCH, 2015, 75
[24] Inhibition of PI3K induces rac activation and membrane ruffling in proto-Dbl expressing cells
Vanni, Cristina
Visco, Vincenzo
Mancini, Patrizia
Parodi, Alessia
Ottaviano, Catherine
Ognibene, Marzia
Manazza, Andrea D.
Retta, Saverio Francesco
Varesio, Luigi
Torrisi, Maria Rosaria
Eva, Alessandra
CELL CYCLE, 2006, 5 (22) : 2657 - 2665
[25] P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib
Zhou, Xiao-ru
Li, Xiao
Liao, Li-ping
Han, Jie
Huang, Jing
Li, Jia-cheng
Tao, Hong-ru
Fan, Shi-jie
Chen, Zhi-feng
Li, Qi
Chen, Shi-jie
Ding, Hong
Yang, Ya-xi
Zhou, Bing
Jiang, Hua-liang
Chen, Kai-xian
Zhang, Yuan-yuan
Huang, Chuan-xin
Luo, Cheng
ACTA PHARMACOLOGICA SINICA, 2022, 43 (02) : 457 - 469
[26] P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib
Xiao-ru Zhou
Xiao Li
Li-ping Liao
Jie Han
Jing Huang
Jia-cheng Li
Hong-ru Tao
Shi-jie Fan
Zhi-feng Chen
Qi Li
Shi-jie Chen
Hong Ding
Ya-xi Yang
Bing Zhou
Hua-liang Jiang
Kai-xian Chen
Yuan-yuan Zhang
Chuan-xin Huang
Cheng Luo
Acta Pharmacologica Sinica, 2022, 43 : 457 - 469
[27] Development of Optimized Protocol for Generation of NK Cells Expressing Chimeric Antigen Receptors from Hematopoietic Stem Cells for Cancer Immunotherapy
Patel, Amie
Truscott, Laurel Christine
De Oliveira, Satiro N.
BLOOD, 2015, 126 (23)
[28] T Cells Expressing Anti B-Cell Maturation Antigen Chimeric Antigen Receptors for Plasma Cell Malignancies
Li, Chunrui
Wang, Qiuxiang
Zhu, Hui
Mao, Xia
Wang, Ying
Zhang, Yicheng
Zhou, Jianfeng
BLOOD, 2018, 132
[29] T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia
Mardiros, Armen
Forman, Stephen J.
Budde, Lihua E.
CURRENT OPINION IN HEMATOLOGY, 2015, 22 (06) : 484 - 488
[30] Effect of Rituximab On the Activity of T Cells Expressing CD20-Specific Chimeric Antigen Receptors
Rufener, Gregory A.
Jensen, Michael C.
Brouns, Shaunda
Budde, Lihua E.
Maloney, David G.
Press, Oliver W.
Till, Brian G.
BLOOD, 2012, 120 (21)

← 1 2 3 4 5 →